Stay well informed

Investor News

We would like to inform you about the current business development of HAEMATO AG as well as about our investor relations activities.

Investor News

HAEMATO AG announces figures for the first quarter of 2022. According to these figures, the Group's consolidated revenue fell to EUR 54.6 million in the first quarter (previous year: EUR 73.9 million). EBITDA fell from EUR 2.8 million in the same quarter of the previous year to EUR 2.3 million. EBIT amounted to EUR 2.0 million in the first …

Investor News

Berlin, May 3, 2022 - At today's balance sheet meeting, the annual financial statements 2021 of HAEMATO AG, which were issued with an unqualified audit certificate, were adopted. The preliminary figures were confirmed. The Executive Board and Supervisory Board will propose a dividend of EUR 1.10 per dividend-bearing share to the Annual General …

Investor News

Renewed increase in sales and strong rise in earnings after disproportionate growth of the new Lifestyle and Aesthetics business unit. HAEMATO remains on course for growth: according to preliminary IFRS financial statements, consolidated revenue in the 2021 financial year rose again by around 20% to EUR 285.0 million, after revenue growth of a good …

Investor News

In its meeting today, the Supervisory Board of HAEMATO AG appointed Mr. Attila Strauss to the Executive Board of HAEMATO AG with effect from 01.04.2022. Mr. Attila Strauss has already been working as Chief Operating Officer at HAEMATO PHARM GmbH since 01.05.2021 and has also been Managing Director of the company since 01.10.2021.

Investor News

HAEMATO PHARM GmbH ("HAEMATO"), a 100% subsidiary of HAEMATO AG (ISIN: DE000289VV1), is expanding its medical device portfolio in the fight against Corona virus. In addition to the already introduced Point-of-Care (PoC) PCR device, HAEMATO is now also marketing the Mini Dock, an alternative PoC device that sets a benchmark in terms of price.

Investor News

With the current omicron wave, laboratories in Germany are facing a sharp increase in PCR testing. The evaluation capacities are pushing increasingly towards their limits, especially with regards to the new quarantine regulations.

For investors

Do you have any further questions about the group? Our investor relations team is happy to help you..

Contact us